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Purpose or Objective 
There is a steady rise in the use of Stereotactic Body 
RadioTherapy (SBRT) in oligometastatic disease (OMD). 
Besides a positive impact on patients’ outcome, this may 
generate important financial consequences for 
radiotherapy budgets. Awaiting more clinical evidence, 
the Belgian compulsory health insurance system initiated 
a coverage with evidence development (CED) project for 
innovative radiotherapy, including SBRT, in 2011. 
Consequently, a provisional financing to treat OMD with 
SBRT was available in Belgium from 2013 onwards.    
While analysis of the clinical and technical data captured 
between 9-2013 and 12-2017 is ongoing and inclusion in 
the formal reimbursement system pending, a cost-
calculation and budget impact analysis (BIA) was carried 
out. 
Material and Methods 
Using the CED data, the uptake of SBRT in patients with 
OMD in Belgium between 2013 and 2017 was reviewed. 
Based on these data, predictive growth scenarios for 
future uptake were developed.  The cost of an SBRT 
treatment in the OMD setting in Belgium was calculated 
using the Health Economics in Radiation Oncology Time-
Driven Activity-Based Costing (HERO TD-ABC) model 
developed by ESTRO, alimented with national data on 
resources, treatments and operational parameters. 
Combining all this information, the future impact of this 
novel treatment indication on the radiotherapy budget in 
Belgium was evaluated. 
Results 
The CED data showed a large increase in number of OMD 
treated with SBRT in Belgium: from 59 in 2013 to 459 in 
2017. Based on this, three growth scenarios for uptake 
were developed: scenario 1, predicting a further linear 
increase; scenario 2, only accounting for demographic 
shift; and an ‘intermediate’ scenario 3 with linear 
increase for two more years, then plateauing to the 
demographic trends (Figure 1).   
 
 
 
Using the HERO TD-ABC model, a real-life cost of 4,359 € 
per SBRT treatment was calculated, whereas the 
provisional financing within the CED program amounted to 
3,802 €.   
The 3 growth scenarios and the costs were combined to 
estimate the impact on the radiotherapy budget. For the 
TD-ABC costs, all OMD SBRT treatments were considered 
new indications, hence, additional SBRT courses and costs. 
For the CED financing data, 2 comparator scenarios were 
assumed. In the comparator 1 scenario, the SBRT courses 
for patients treated in the OMD setting are all considered 
additional SBRT courses. In the comparator 2 scenario, 50% 
of the SBRT courses are considered new cases and 50% are 
considered as previously treated with palliative intent, 
leading to a lower cost increment. Table 1 demonstrates 
the financial impact of the different scenarios.  
 
 
 
Conclusion 
The possible impact on the radiotherapy budget of uptake 
of SBRT for OMD shows large variations. These data should 
be evaluated in the context of improved outcome and set 
against the background of the actual Belgian radiotherapy 
budget amounting to roughly 120 million €.  Further real-
life clinical and financial monitoring and prospective data 
gathering seems necessary. 
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Purpose or Objective 
Interest in MRI for external beam radiotherapy (EBRT) 
planning is growing, as is the need for consensus guidelines 
for its use in the UK. In response to this, IPEM will report 
guidelines on MRI use for EBRT planning. As a first step, an 
audit has been performed to assess the current UK 
landscape of MRI in EBRT and the results are presented 
here. 
Material and Methods 
IPEM has supported a multidisciplinary working group, who 
developed a survey to assess the current landscape and 
needs of institutions regarding MRI in EBRT.  The survey 
was split into six sections covering: institution details and 
MRI access; MRI use at the institution; MRI to CT 
registration; commissioning, QA and safety of MRI 
scanners; workflow, staffing and training; and, future 
applications of MRI. The survey was sent to 71 UK 
departments (63 NHS and 8 private groups) in June 2018 
and closed after 8 weeks.  
Results 
Responses were obtained from 62/71 centres (87%) with 
good engagement from both NHS centres (89%) and private 
groups (75%). Of the responders, 94% use MRI for 
radiotherapy treatment planning taken from PACs, 
potentially acquired at another institution or not 
optimised for radiotherapy purposes. 69% of responders 
have some access to an MRI scanner for EBRT, ie in some 
format where they have control over the MRI acquisition, 
see figure. It was reported that there are only two 
dedicated MRI-simulators in the UK.   
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All centres using MRI in EBRT use rigid MRI to CT 
registration and two centres are currently using 
deformable image registration in addition. Commissioning 
and QA of image registration and MRI for EBRT showed 
large inter-centre heterogeneity caused by a lack of 
guidance. 
Physics support for setting up a new MRI for EBRT service 
is varied across the UK with links with radiology being very 
important and 23% of centres reporting no support from 
physics staff with specialist MRI knowledge.   
The largest reported barrier to utilising MRI further is a 
lack of MRI access (87% of centres) but a large proportion 
of all concerns are financially driven with a lack of tariff 
meaning centres do not get reimbursed for an MRI scan, 
see figure.  
 
 
 
Looking forward, within the next five years,  37% of 
centres intend to use functional MRI, 38% of centres are 
planning for an MRI-simulator, 16% of centres are planning 
to utilise MRI-only radiotherapy and 10% are planning for 
an MRI-linac (on top of the 3% that currently have access).  
Conclusion 
The current use of MRI for EBRT in the UK was audited. 
More than 2 in 3 of centres have some form of MRI access, 
but there are only 2 MRI-simulators at present. 
Collaboration with radiology departments is vital for both 
MRI access and staff support. The main barriers to fully 
integrate MRI are financially driven and a lack of tariff 
resulting in limited access. Knowledge gaps have been 
identified such as the lack of standardised QA guidance 
that will be addressed in the IPEM guidelines.   
 
